Boston Scientific Corporation has announced significant advancements in the use of artificial intelligence $(AI)$ to predict and prevent cardiac emergencies. Their AI technology is transforming healthcare by shifting from reactive to proactive and predictive medicine, enhancing the quality of care through early diagnoses and intervention. The company's HeartLogic™ Heart Failure Diagnostic, the first FDA-approved predictive analytic alert in an implantable device, is helping identify patients at risk for worsening heart failure weeks before symptoms appear. This innovative technology analyzes various physiological biomarkers, enabling the prediction of up to 70% of heart failure cases approximately 34 days in advance, thereby allowing physicians valuable time to intervene and potentially prevent emergencies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。